Access and Evidence
Make All Phase 3 Studies Pragmatic
Rafael Alfonso explains why pharma needs to resolve and merge the differing evidence requirements of regulators and payers.
More Access and Evidence Articles
Access and Evidence
Latin America’s Pharmaceutical Prices: The Perfect Storm is Here
How prepared are pharma for Latin America's pricing storm?
Access and Evidence
Greek Crisis Calls: Time for Pharma to Step Up
Pharma must prove its patient centric credentials by offering a solution based on compromise and collaboration.
Access and Evidence
Hospira Buoyed by Real World Evidence
US firm seeks to build on success of its Remicade copy, Inflectra with real-world studies.
Access and Evidence
Making Sense of Data
AstraZeneca’s elite computer scientists are turning their skills to drug development.
Access and Evidence
RWD – Will the Promise be Fulfilled?
What are the challenges around access to & the collection of RWD from a UK and European perspective?
Access and Evidence
Public-Private Partnerships Essential for Public Health Education
How is the pharmaceutical industry currently contributing to public health education?
Access and Evidence
Lack of Adherence Data – Is Pharma in the Dark?
A mere 14% of pharma think they have sufficient medication adherence data for all products in their portfolio says S3 Survey.
Access and Evidence
Scotland: Doing Things Differently
Doubling of Scottish New Medicines Fund: Good or Bad?
Access and Evidence
Biosimilars: Poised for Takeoff?
Sue Naeyaert, Head, Global Pricing and Market Access Biosimilars, Merck Serono discusses ongoing challenges as biosimilars continue to evolve.